Iovance Biotherapeutics surges after historic cell therapy approval
Arctic Aurora LifeScience and Biotech Select holding Iovance appreciated 94% year to date including 72% after the approval of their cell therapy treatment in advanced skin cancer.
When a tumor develops, our immune system recognizes and attacks it. There is a select group of immune cells that are able to eliminate tumor cells. These cells are unique to each patient and each tumor. However, as cancer progresses, it evades these specific cells and they become depleted.
The core idea of Iovance's new therapy is to take these natural cancer-fighting immune cells from the patient, re-invigorate and expand them, and give them back to the patient so they can more effectively eliminate tumor cells.
On February 16, the FDA approved the first such drug, AMTAGVI, for advanced skin cancer, or melanoma, a disease that kills 8,000 people each year in the U.S. alone. The approval is based on a Phase 3 trial in which the therapy produced deep and durable responses in patients who had no other options. This makes AMTAGVI the first approved individualized cell therapy for solid tumors. AMTAGVI is also being tested in several other tumors, including cervical and lung cancer. Based on this positive news, sales of the drug are expected to reach USD 900 million by the end of the decade.
Latest news
Arctic Asset Management - Apellis to be acquired by Biogen for 140% premium
On March 31, Arctic Aurora LifeScience portfolio company Apellis Pharmaceuticals announced that the company had agreed to be acquired by Biogen for an upfront cash consideration of USD 5.6 billion, representing a 140% premium on the latest closing price.
Arctic Asset Management - Arctic Midt i Måneden - Global uro, energisjokk og markedsmuligheter
Geopolitisk uro, stigende energipriser og økt markedsvolatilitet preger finansmarkedene i mars. Hva betyr dette for renter, aksjer og investorers posisjonering fremover? I denne episoden av Arctic Midt i Måneden diskuterer Albert Collett sammen med Cathrine Foyn, Tone Varmann og Alexander Larstedt Lager hvordan krig og usikkerhet påvirker markedene – og hvor mulighetene kan ligge i en urolig tid.
Arctic Asset Management - Unlocking Alpha in Biotech Through Active Selection
Yesterday, two companies in the Arctic Aurora LifeScience portfolio reported positive clinical data, which was rewarded by the market. Clinical execution and identifying companies with differentiated drug candidates yields excess returns, as demonstrated by Xenon's share price, which appreciated by close to 50% on positive data, and Dianthus, which appreciated by 21%.
Arctic Asset Management - An AI sector winner
Artificial intelligence (AI) is often portrayed as a disruptive force. In the pharmaceutical and biotechnology industries, however, it should primarily be understood as a structural value driver, enhancing productivity, improving capital efficiency and strengthening long-term competitive positioning. By compressing timelines in the discovery process and improving efficiency at the clinical and commercial stages, AI-based tools can reduce costs and meaningfully improve industry economics.
Arctic Asset Management - Markedskommentar februar 2026
I februar 2026 ble markedene påvirket av skiftende forventninger til amerikanske rentekutt, ettersom inflasjons- og arbeidsmarkedsdata var noe motstridende. Investorene fortsatte å spekulere i hvor lenge Federal Reserve ville holde politikken uendret. Store teknologi- og AI-aksjer svingte kraftig da resultater og utsikter fra ledende chip- og plattformselskaper flyttet indeksene markant. Traden bort fra programvare-aksjer fortsatte. Handelspolitikken ble også en gjentakende risikofaktor: USAs høyesterett kjente sentrale tolltiltak ulovlige, etterfulgt av nye tollgrep som økte usikkerheten for globale selskaper og verdikjeder. Mot slutten av måneden kom finanssektoren under press da bankaksjer falt på økt fokus på private-kreditt-eksponeringer og likviditetsvilkår i privatkredittprodukter rettet mot private investorer. Geopolitikk dreide seg mye om USA–Iran-spenninger og forstyrrelser på oljeprisen.
Arctic Asset Management - Arctic Midt i Måneden - Midt i rapporteringssesongen
Vi er halvveis i rapporteringssesongen, og i denne episoden av Arctic Midt i Måneden tar vi temperaturen på norske og nordiske selskaper. Hvordan har resultatene kommet inn relativt til forventningene? Hvilke sektorer leverer – og hvor straffer markedet hardest? Vi diskuterer store bevegelser på enkeltrapporter, effekten av valuta og råvarepriser, og økende marginpress i enkelte bransjer. Alexander Lager Larstedt og Herman Østensen er gjester i studio hos Albert Collett.